UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide
Status:
Terminated
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
Add three drugs, bortezomib, thalidomide, and dexamethasone (VTD) to the high dose
chemotherapy regimen immediately before transplant (DPACE/Melphalan) to try to improve
myeloma response and acquire longer survival for participants.